References
- Kleinke JD. Just what the HMO ordered: the paradox of increasing drug costs. Health Affairs 19(2), 78–91 (2000).
- Chemew M, Cowen ME, Kirking DM, Smith DG, Valenstein P, Fendrick AM. Pharmaceutical cost growth under capitation: a case study. I-kalth Affairs 19(6), 266–276 (2000).
- Levitt K, Cowan C, Braden B, Stiller J, Sensenig A, Lazenby H. National health expenditures in 1997: more slow growth. Health Affairs 17 (6), 99–110 (1999).
- Anis AH. Substitution laws, insurance coverage, and generic drug use. Merl Cate 32(3), 240–256 (1994).
- Motheral BR, Henderson R. The effect of a closed formulary on prescription drug use and costs. Inquiry 36,481–491 (1999).
- Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc. Sci. Merl 45(4), 535–544 (1997).
- Olmstead T, Zeckhauser R. The menu- setting problem and subsidized prices: drug formulary illustration. j Health Econ. 18, 523–550 (1999).
- Dranove D, White WD. Agency and the organization of health care delivery. Inquiry 24,405–415 (1987).
- •Provides an overview of the principal—agent relationship and its application to healthcare.
- Sloan FA, Gordon GS, Cocks DL. Hospital formularies and use of hospital services. Merl Cate 31(10), 851–867 (1993).
- Leibowitz A, Manning WG, Newhouse JR The demand for prescription drugs as a function of cost-sharing. Soc. Sci Merl 21(10), 1063–1069 (1985).
- Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, Brook RII. The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial. j Chron. Dis. 40 (5), 429–437 (1987).
- Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Mlbank Qrtly. 71(2), 217–252 (1993). Gives a review of the pharmaceutical cost-containment literature and outlines important considerations in the design of a drug reimbursement study.
- Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Am. j Man. Cate 8(1), 69–76.
- ••Provides an overview and critique of theliterature examining restrictive formularies.
- Schweitzer SO, Shiota SR. Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals. Ann. Rev Pub. Health 13, 399–410 (1992).
- Moore WJ, Newman RJ. Drug formulary restrictions as a cost-containment policy in Medicaid programs. J. Law Econom. 36 (April), 71–97 (1993).
- Lewis JH, Schonlau M, Mufloz JA. Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries. N. Eng: J. Med. 346 (11), 830–835 (2002).
- Spigset 0, Mar' tensson B. Drug treatment of depression. Brit. Med J. 318,1188-1191 (1999).
- Gorecki PK. A comparison of two drug reimbursement pricing models: B.C. Pharamcare and the Ontario Drug Benefit Programme. Can. J. Econ. 26(4), 867–877 (1993). Gives a background on best available price.
- Anis, AH. Pharmaceutical prices with insurance coverage and formularies. Can. J. Econ. 25(2), 420–437 (1992).
- Spino M, Tsang YC, Pop R. Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs. Eur. Drug- Metab. Pharmacokinetics 25(1), 18–24 (2000).
- Lindsey R, West DS. National pharmacare, reference based pricing, and drug R&D: a critique of the national forum on healths recommendations for pharmaceutical policy. Can. Pub. Policy XXV (1), 1–27 (1999).
- ••Provides an overview of the literature onreference-based pricing.
- Dickson M.The pricing of pharmaceuticals: an international comparison. Clin. Therapeutics 14(4), 604–610 (1992).
- Selke GW. Reference price systems in the European community. In: Cost Containment Pricing- Financing- of Pharmaceuticals in the European Community: Policymakels View Mossialos E, Ranos C, Abel-Smith B (Eds). LSE Health and Pharmetrica SA, London, UK (1994).
- Scott A. Reference pricing: a sham and a shambles. In: Healthy Incentives: Canadian Health Reform in an International Context McArthur WJ, Ramsay C, Walker M (Eds). The Fraser Institute, Vancouver, Canada, 91–99 (1996).
- Moore D, Scott A. The great debate about reference pricing of pharmaceuticals. In: Healthy Incentives: Canadian Health Reform in an International Context. McArthur WJ, Ramsay C, Walker M (Eds). The Fraser Institute, Vancouver, Canada, 103–108 (1996).
- Ulrich V, Wille E. Healthcare reform and expenditure on drugs. PharmacoEconomics 10\(Suppl. 2), 81–88 (1996).
- Bosanquet N, Zammit-Lucia J. The effect of competition on drug prices. PharmacoEconomics8(6), 473–478 (1995).
- Schneeweiss S, Schöffski 0, Selke GW. What is Germanys experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 44,253–260 (1998).
- Bourgault C, Elstein E, Le Lorier J, Suissa S. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. Can. Med Assoc. J. 161,255–260 (1999).
- Grootendorst P, Holbrook A. Evaluating the impact of reference-based pricing. Can. Med. Assoc. J. 161,273–274 (1999).
- Narine L, Senathirajah M, Smith T Evaluating reference-based pricing: initial findings and prospects. Can. Med. Assoc. J. 161,286–288 (1999).
- Kent H. BC's reference-based pricing stirs controversy. Can. Med. Assoc. J. 162,1190 (2000).
- Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors. N. Eng. J Med 346,822–829 (2002).
- Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impacts of reference pricing for ACE inhibitors on drug utilization. Can. Med. Assoc. J. 166,737–748 (2002).
- Morgan S. Quantifying components of drug expenditure inflation: the British Columbia Seniors Drug Benefit Plan. Health Services Res. 37,1243-1266 (2002). 036Tamblyn R, Laprise R, Hanley JA et al Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAIVIA 285,4421–429 (2001).
- Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs in Medicaid: effects on therapy, cost and equity. N Eng. I Med. 317,550-556 (1987).
- Anis A. Why is calling an ACE and ACE so controversial? Evaluating reference-based Pricing in British Columbia. Can. Med. Assoc. J. 166,763–764 (2002).
- Schneeweiss S, Maclure M, Walker AM, Grootendorst P, Soumerai SB. On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy 55,97-109 (2002). A review of the pharmaceutical cost-containment literature and outlines important considerations in the design of a drug reimbursement study.
- Segedin DA. Three-tier copayment plans: design considerations and effectiveness. Drug Benefit 7i-ends 11(9), 43–52 (1999).
- •Provides an overview of one multitier formulary model.
- Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients. Brit. Med J. 312,1469-1471 (1996).
- Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am. Econom. Rev 77(3), 251–277, (1987).
- Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry22,396–403 (1985).
- Harris BL, Stergachi A, Pied LD. The effect of drug copayments on utilization and cost of pharmaceuticals in a HMO. Medical Care 28(10), 907–917 (1990).
- Newhouse JF'. Fire For Alrlassons from the RAND Health Insurance Everiment. Harvard University Press, Cambridge, USA (1993).
- Hillman A, Pauly M, Escarce J eta]. Financial incentives and drug spending in managed care. Health Affairs 18(2), 189–200, (1999).
- Latimer EA, Tamblyn R, Laprise R et al Net economic impact of a reduction in drug insurance coverage for mentally ill welfare recipients in Quebec. Working Paper. Doug as Hospital Research Centre. (1999).
- Motheral B, Fairman IKA. Effect of a three- tier prescription copay on pharmaceutical and other medical utilization. Medical Care 39(12), 1293–1304 (2001).
- National Institute for Health Care Management Research and Educational Foundation (NIHCM). A primer: generic drugs, patents and the pharmaceutical marketplace. A forthcoming report, 1–28 (2002). Expert Rev. Phannacoeconomics Outcomes Res. 3 (3), (2003)
- Carroll NV, Fincham JE, Cox FM. The effects of differences in state drug product selection laws on pharmacists' substitution behavior. Med. Cate 25(11), 1069–1077 (1987).
- Lipton HL, Kreling DH, Collins T, Hertz KC. Pharmacy benefit management companies: dimensions of performance. Ann. Rev. Pub. Health 20, 361–401 (1999).
Websites
- Canadian Institute for Health Information (CIHI). Health Care in Canada. http:// secure.cihi.ca/cihiweb/hcic/hcic.html (Accessed 16 August, 2002).
- Drug Benefit Trends. Three-tier copayments facilitate cost and utilization management. 14(2), 7 www.medscape.com/viewarticle/424378 (Accessed 19 July, 2002).
- Dalzell MD. Pharmacy copayments: a double-edged sword. Managed Care www.managedcaremag.com/arch1ves/9908/ 9908.pharmcopay (Accessed 25 September 2002).
- National Institute for Health Care Management Research and Education Foundation (NIHCM). Changing patterns of Pharmaceutical Innovation (2002). www.nihcm.org/innovations.pdf.